Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands. Issue 2 (8th January 2021)

• Record Type: Journal Article
• Authors: Peckeu, L.; van der Ende, A.; de Melker, H.E.; Sanders, E.A.M.; Knol, M.J.
• Is Part Of: Vaccine. Volume 39:Issue 2(2021)
• Page Start: 431
• Page End: 437
• Publication Date: 2021-01-08
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.11.018
• Languages: English
• ISSNs: 0264-410X

Abstract

Highlights: PCV10 is highly effective against IPD in Dutch children <5 years. Limited serotype replacement in childhood IPD occurred over time. No evidence for significant cross-protection of PCV10 against serotype 19A IPD. Abstract: Background: In 2011, the 7-valent pneumococcal conjugate vaccine (PCV7) was replaced by the 10-valent vaccine (PCV10) in the Netherlands. We report on impact and effectiveness against invasive pneumococcal disease (IPD) in children aged under 5 years by switching from PCV7 to PCV10. Method: We included IPD cases between 2004 and 2019 in children aged < 5 years reported via the national surveillance system. To assess the impact of the PCV10 vaccination program we compared IPD incidence 6-8 years after PCV10 introduction (2017–2019) to the two years just before the switch to PCV10 (2009–2011). We estimated vaccine effectiveness (VE) using the indirect cohort method, comparing vaccination status (at least two vaccine doses) in IPD-cases caused by PCV10 serotypes (cases) to non-PCV10 IPD cases (controls), in children eligible for PCV10. Results: The overall incidence decreased from 8.7 (n = 162) in 2009–2011 to 7.3 per 100.000 (n = 127) in 2017–2019 (Incidence rate ratio (IRR) 0.83, 95%CI: 0.66; 1.05). IPD caused by the additional serotypes included in PCV10 declined by 93% (IRR 0.07, 95%CI: 0.02; 0.23). Incidence of non-PCV10 IPD showed a non-significant increase (IRR 1.25, 95%CI: 0.96; 1.63). Among 231 IPD-cases eligible for PCV10, the overall VE was 91% (95%CI: 67; 97) and did not differ by sex or age at diagnosis. Effectiveness against non-PCV10 serotype 19A IPD was non-significant with an estimate of 28% (95%CI:-179; 81). Conclusion: PCV10 is highly effective in protecting against IPD in Dutch children under 5 years with limited serotype replacement after switching from PCV7 to PCV10. We found no evidence for significant cross-protection of PCV10 against 19A serotype IPD.